Eli Lilly’s Next $2.9 Billion Bet Is Not About Obesity
LLY
Pharmaceutical giant Eli Lilly and Co. (LLY, Financials) said it agreed to buy Merida Biosciences for up to $2.875 billion in cash as it expands beyond its dominating obesity and diabetes franchises
The upfront and milestone payments are part of an agreement that is slated to close in the fourth quarter of 2026, subject to regulatory approvals
Merida is developing biologics that selectively destroy disease-causing autoantibodies while preserving normal immune function
Its flagship program, MER511, is in Phase 1 testing for Graves’ illness and thyroid eye condition. The deal adds another potential growth platform beyond weight-loss for Lilly
It has also been expanding its pipeline in immunology and other therapeutic areas, lowering its long-term dependence on blockbuster drugs such as Mounjaro and Zepbound
The financial risk is that Merida’s lead asset is still early in development. Lilly is betting billions of dollars on a platform that still has to cross a number of clinical and regulatory obstacles before it can generate considerable income
The upside is larger. If it succeeds in numerous antibody-driven diseases, Lilly might have a technology platform rather than just a single therapeutic candidate, said Merida
So now investors will be watching the early MER511 data and whether Lilly can extend the technique into other autoimmune conditions
GuruFocusMergers and acquisitionsUS stocks
Read more from GuruFocus
